Recent Finacing
Recent Raise
X4 Pharmaceuticals develops orally administered CXCR4 inhibitors, markets mavorixafor (XOLREMDI) in the U.S., and runs global clinical programs in rare immune disorders (WHIM, chronic neutropenia) and oncology.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at X4 Pharmaceuticals.
